ConditionCardiac Inflammation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentral Hospital, Nancy, France
About this trial
Gallium-68-DOTATOC binds primarily with high affinity to somatostatin subtype 2 (SSTR2) receptors and these somatostatin receptors are also overexpressed on inflammation cells when activated.
The hypothesis is that the GATED mode on a Gallium-68-DOTATOC cardiac recording would be able to highlight abnormalities that could be correlated with the age of the patients and their cardiovascular risk factors.
Eligibility criteria
Qualifiers
Age ≥ 18 years old.
Having read and understood the information document.
Affiliated to a social security scheme.
Disqualifiers
Hypersensitivity during previous use of 68Ga-DOTATOC
Impossibility of performing a PET-CT (patient agitated, confused, etc.).
History of heart disease,
Severe arrhythmia that does not allow the PET synchronized with the ECG
Trial design
Treatments tested in this trial
- Cardiac ECG-gated PET imaging will added
Treatment groups
99 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov